Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients

被引:15
作者
Zver, Tristan [1 ,2 ,3 ]
Frontczak, Sophie [1 ,2 ,3 ]
Poirot, Catherine [4 ]
Rives-Feraille, Aurelie [5 ]
Leroy-Martin, Brigitte [6 ]
Koscinski, Isabelle [7 ]
Arbez-Gindre, Francine [8 ]
Garnache-Ottou, Francine [2 ]
Roux, Christophe [1 ,2 ,3 ]
Amiot, Clotilde [1 ,2 ,3 ]
机构
[1] CHU Besancon, CECOS Bourgogne Franche Comte, Serv Biol & Med Reprod, Cryobiol, F-25000 Besancon, France
[2] Univ Bourgogne Franche Comte, INSERM, EFS BFC, UMR1098,RIGHT Interact Hote Greffon Tumeur Ingn C, F-25000 Besancon, France
[3] CHU Besancon, INSERM CIC 1431, F-25000 Besancon, France
[4] Hop St Louis, Serv Hematol, Unite AJA, F-75010 Paris, France
[5] CHU Rouen, Ctr Assistance Med Procreat CECOS, F-76000 Rouen, France
[6] CHU Lille, Lab Biol Reprod, CECOS, Spermiol, F-59000 Lille, France
[7] CHRU Nancy, CECOS, Serv Biol Reprod, F-54035 Nancy, France
[8] CHU Besancon, Serv Anat Pathol, F-25000 Besancon, France
关键词
Multicolor flow cytometry; Minimal residual disease; Ovarian tissue cryopreservation; Fertility preservation; ACUTE LYMPHOBLASTIC-LEUKEMIA; FERTILITY PRESERVATION; CHILDHOOD-CANCER; CELL CONTAMINATION; COMPLETE REMISSION; TRANSPLANTATION; SURVIVORS; CORTEX; CHEMOTHERAPY; PREGNANCY;
D O I
10.1186/s13048-021-00936-4
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Cryopreservation of ovarian tissue is a fertility-preservation option for women before gonadotoxic treatments. However, cryopreserved ovarian tissue transplantation must be performed with caution in women with malignancies that may metastasize to the ovaries. For this purpose, detecting minimal residual disease (MRD) in the ovarian cortex using sensitive methods is a crucial step. We developed an automated ovarian tissue dissociation method to obtain ovarian cell suspensions. Results We assessed MRD by multicolor flow cytometry (MFC) in cryopreserved ovarian cortex of 15 leukemia patients: 6 with B-cell acute lymphoblastic leukemia (B-ALL), 2 with T-cell acute lymphoblastic leukemia (T-ALL) and 7 with acute myeloid leukemia (AML). Ovarian MRD was positive in 5 of the 15 leukemia patients (one T-ALL and 4 AML). No B-ALL patient was positive by MFC. Quantitative reverse-transcribed polymerase chain reaction was performed when a molecular marker was available, and confirmed the MFC results for 3 patients tested. Xenografts into immunodeficient mice were also performed with ovarian cortical tissue from 10 leukemia patients, with no evidence of leukemic cells after the 6-month grafting period. Conclusions In conclusion, this is the first study using MFC to detect MRD in ovarian cortical tissue from acute leukemia patients. MFC has been accepted in clinical practice for its ease of use, the large number of parameters available simultaneously, and high throughput analysis. We demonstrate here that MFC is a reliable method to detect MRD in cryopreserved ovarian tissue, with a view to controlling the oncological risk before ovarian tissue transplantation in leukemia patients.
引用
收藏
页数:11
相关论文
共 64 条
[1]   Ovarian minimal residual disease in chronic myeloid leukaemia [J].
Abir, Ronit ;
Aviram, Adina ;
Feinmesser, Meora ;
Stein, Jerry ;
Yaniv, Isaac ;
Parnes, Doris ;
Ben-Haroush, Avi ;
Meirow, Dror ;
Rabizadeh, Esther ;
Fisch, Benjamin .
REPRODUCTIVE BIOMEDICINE ONLINE, 2014, 28 (02) :255-260
[2]   Minimal residual disease detection of leukemic cells in ovarian cortex by eight-color flow cytometry [J].
Amiot, Clotilde ;
Angelot-Delettre, Fanny ;
Zver, Tristan ;
Alvergnas-Vieille, Magalie ;
Saas, Philippe ;
Garnache-Ottou, Francine ;
Roux, Christophe .
HUMAN REPRODUCTION, 2013, 28 (08) :2157-2167
[3]   ESHRE guideline: female fertility preservation [J].
Anderson, Richard A. ;
Amant, Frederic ;
Braat, Didi ;
D'Angelo, Arianna ;
Lopes, Susana M. Chuva de Sousa ;
Demeestere, Isabelle ;
Dwek, Sandra ;
Frith, Lucy ;
Lambertini, Matteo ;
Maslin, Caroline ;
Moura-Ramos, Mariana ;
Nogueira, Daniela ;
Rodriguez-Wallberg, Kenny ;
Vermeulen, Nathalie .
HUMAN REPRODUCTION OPEN, 2020, 2020 (04)
[4]   Minimal residual disease of leukemia and the quality of cryopreserved human ovarian tissue in vitro [J].
Asadi-Azarbaijani, Babak ;
Sheikhi, Mona ;
Nurmio, Mirja ;
Tinkanen, Helena ;
Juvonen, Vesa ;
Dunkel, Leo ;
Hovatta, Outi ;
Oskam, Irma C. ;
Jahnukainen, Kirsi .
LEUKEMIA & LYMPHOMA, 2016, 57 (03) :700-707
[5]   Chemotherapy-induced damage to ovary: mechanisms and clinical impact [J].
Bedoschi, Giuliano ;
Navarro, Paula Andrea ;
Oktay, Kutluk .
FUTURE ONCOLOGY, 2016, 12 (20) :2333-2344
[6]   Safety of Ovarian Tissue Autotransplantation for Cancer Patients [J].
Bockstaele, Laurence ;
Tsepelidis, Sophie ;
Dechene, Julie ;
Englert, Yvon ;
Demeestere, Isabelle .
OBSTETRICS AND GYNECOLOGY INTERNATIONAL, 2012, 2012
[7]   Fertility Preservation Options in Pediatric and Adolescent Patients With Cancer [J].
Burns, Karen C. ;
Hoefgen, Holly ;
Strine, Andrew ;
Dasgupta, Roshni .
CANCER, 2018, 124 (09) :1867-1876
[8]   Minimal residual disease monitoring in childhood acute lymphoblastic leukemia [J].
Campana, Dario .
CURRENT OPINION IN HEMATOLOGY, 2012, 19 (04) :313-318
[9]   Minimal residual disease quantification in ovarian tissue collected from patients in complete remission of acute leukemia [J].
Chevillon, Florian ;
Clappier, Emmanuelle ;
Arfeuille, Chloe ;
Cayuela, Jean-Michel ;
Dalle, Jean Hugues ;
Kim, Rathana ;
Caye-Eude, Aurelie ;
Chalas, Celine ;
Abdo, Chrystelle ;
Drouineaud, Veronique ;
de Latour, Regis Peffault ;
Alcantara, Marion ;
Uzunov, Madalina ;
Degaud, Michael ;
Meignin, Veronique ;
Dombret, Herve ;
Boissel, Nicolas ;
Poirot, Catherine ;
Dhedin, Nathalie .
BLOOD, 2021, 137 (12) :1697-1701
[10]  
*CHILDH CANC COLL, 2019, LANCET ONCOL, V20, P1211